Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO & EHA 2023 MPN Highlights
27 June 2023 | Virtual Meeting
Expert-led presentations & discussions on key abstracts in MPNs from ASCO and EHA 2023
The Post-ASCO & EHA 2023 MPNs Highlights was supported by Karyopharm Therapeutics and Kartos Therapeutics. Supporters have no influence over the production of content.
Session 1
ACE-536-MF-001: Luspatercept for anemia in patients with MF
Francesco Passamonti University of Insubria, Varese, Italy
Hovon-134: pacritinib before reduced-intensity conditioning ASCT
Ruben Van Dijck Erasmus University Medical Centre, Rotterdam, Netherlands
PERSIST-2: SVR predicts survival in MF patients on pacritinib
Jan Bewersdorf Yale Cancer Center, New Haven, CT, United States
Panel discussion
Session 2
XPORT-MF-034: SEL + RUX in JAKi treatment-naïve patients with MF
Srinivas Tantravahi University of Utah, Salt Lake City, UT, United States
Addition of navtemadlin to RUX for primary or secondary MF
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Zilurgisertib as monotherapy or with RUX in patients with anemia
Prithviraj Bose The University of Texas MD Anderson Cancer Center, Houston, TX, United States
BMS-986158 + RUX or FED in intermediate- or high-risk MF
Haifa Kathrin Al-Ali Martin Luther University of Halle-Wittenberg, Halle, Germany
Panel discussion
Session 3
MYLOX-1: GB2064 in patients with MF
Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
Elotuzumab in patients with MF
Prithviraj Bose The University of Texas MD Anderson Cancer Center, Houston, TX, United States
TP-3654 shows cytokine reduction and clinical responses in R/R MF
Firas El Chaer University of Virginia, Charlottesville, VA, United States
TL-895 for MF patients with severe thrombocytopenia
Michael Loschi Nice University Hospital, Nice, France
Panel discussion
Session 4
MANIFEST: pelabresib for high-risk ET refractory or intolerant to hydroxyurea
Francesco Passamonti University of Insubria, Varese, Italy
An update on avapritinib therapy
Deepti Radia Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
JAK2-CHIP is associated with similar risk of CVD as JAK2-MPNs
Jeremy Grevet Massachusetts General Hospital, Boston, MA, United States
Rusfertide improves PV-related symptoms
Andrew Kuykendall Moffitt Cancer Center, Tampa, FL, United States
Panel discussion
The Post-ASCO & EHA 2023 MPNs Highlights webinar has been supported by:
Silver Supporters
